Narcolepsy Market Report 2026

Narcolepsy Market Overview

• Narcolepsy market size has reached to $3.95 billion in 2025 • Expected to grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 10.9% • Growth Driver: Obesity Fueling Narcolepsy Market Growth • Market Trend: Development Of Extended-Release Medications In The Narcolepsy Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

The key promising market opportunities in the narcolepsy market include: • Type 1 (Segmentation By Type) → Expected gain of $1.44 Billion • Type 2 (Segmentation By Type) → Expected gain of $1.12 Billion

What Is Covered Under Narcolepsy Market?

Narcolepsy is a chronic neurological disorder that affects the brain's ability to regulate sleep-wake cycles. People with narcolepsy often experience excessive daytime sleepiness and uncontrollable episodes of falling asleep during the day, which can occur during any type of activity. Narcolepsy is frequently accompanied by cataplexy, a sudden loss of muscle tone triggered by strong emotions. The main types of narcolepsy are type 1 and type 2. Type 1 narcolepsy, also known as NT1, is characterized by excessive daytime sleepiness and cataplexy, which is a sudden loss of muscle tone often triggered by strong emotions. The treatment of narcolepsy includes antidepressants, stimulants, sodium oxybate, and others, and it is diagnosed by a polysomnogram and multiple sleep latency tests. The various end users include hospitals, retail pharmacies, and others.

What Is The Narcolepsy Market Growth Forecast?

The narcolepsy market size is expected to see rapid growth in the next few years. It will grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to rising prevalence of sleep disorders, increasing r&d investment, expanding non-stimulant therapeutic pipeline, growing patient education initiatives, advancements in precision medicine approaches. Major trends in the forecast period include rising awareness and diagnosis of narcolepsy, increasing adoption of combination therapy, growing demand for long-acting therapeutics, expansion of non-stimulant treatment options, enhanced focus on cataplexy-specific therapeutics.

What Is The Driver Of The Narcolepsy Market?

The growing number of obese people is expected to propel the growth of the narcolepsy market going forward. Obesity is a medical condition characterized by an excessive accumulation of body fat, which poses a health risk. The number of obese people is rising due to increasingly sedentary lifestyles, poor dietary habits, and environmental factors that promote calorie-dense food consumption and reduce physical activity. Obesity can contribute to narcolepsy by disrupting metabolic and hormonal balances, potentially leading to changes in sleep patterns and the regulation of wakefulness. For instance, in May 2025, according to the Office for Health Improvement & Disparities, a UK-based government department, an estimated 64.5 percent of adults aged 18 and over in England were overweight or living with obesity in 2023–2024, up from 64.0 percent in 2022–2023, reflecting a continuing upward trend. Therefore, the growing number of obese people is driving the growth of the narcolepsy industry.

How Will The Drivers Impact Growth In The Global Narcolepsy Market?

• Increasing Awareness And Diagnosis Of Narcolepsy (Low) – During the forecast period, the increasing awareness and diagnosis of narcolepsy is expected to become a key growth driver for the narcolepsy market by 2030. Rising awareness among healthcare professionals and the general population is significantly improving diagnosis rates of narcolepsy. Historically underdiagnosed, the condition is now being identified more accurately due to educational campaigns, improved diagnostic tools, and better clinical understanding. Early diagnosis increases demand for treatment options such as medications, behavioral therapy, and patient support programs. Healthcare providers are also more vigilant in identifying symptoms like excessive daytime sleepiness and cataplexy. • Advancements In Pharmacological Treatments (Low) – During the forecast period, the advancements in pharmacological treatments is expected to emerge as a major factor driving the expansion of the narcolepsy market by 2030. Continuous advancements in drug development, including therapies such as pitolisant, modafinil, and armodafinil, are driving market growth. These medications offer improved efficacy, fewer side effects, and better patient adherence compared to older treatments. Pharmaceutical companies are investing in research and clinical trials to develop innovative therapies targeting sleep-wake regulation. Regulatory approvals are expanding access to these drugs across multiple regions. • Growth Of Digital Healthcare And Telemedicine Services (Low) – During the forecast period, the growth of digital healthcare and telemedicine services is expected to act as a key growth catalyst for the narcolepsy market by 2030. The rapid adoption of telemedicine and digital healthcare platforms is improving access to narcolepsy care. Patients can consult specialists remotely, reducing geographical and logistical barriers. Telemedicine supports continuous monitoring and follow-up, which is essential for chronic conditions like narcolepsy. Digital tools such as sleep tracking applications and virtual therapy programs enhance patient engagement and adherence to treatment. This shift toward remote healthcare solutions is particularly beneficial in underserved areas.

How Will The Restraints Impact Growth In The Global Narcolepsy Market?

• High Cost Of Treatment And Limited Reimbursement (Low) – During the forecast period, high cost of treatment and limited reimbursement are significantly restricting the growth of the narcolepsy market. Expensive long-term pharmacological therapies combined with inadequate insurance coverage in many regions are creating financial burdens for patients and limiting treatment accessibility. • Underdiagnosis And Misdiagnosis Of Narcolepsy (Low) – During the forecast period, underdiagnosis and misdiagnosis of narcolepsy are significantly restricting the growth of the narcolepsy market. Overlapping symptoms with other sleep and neurological disorders, along with limited specialist availability, are leading to delayed or incorrect diagnosis, reducing timely treatment initiation. • Side Effects And Safety Concerns Of Medications (Low) – During the forecast period, side effects and safety concerns of medications are significantly restricting the growth of the narcolepsy market. Adverse reactions associated with stimulant and wakefulness-promoting agents are leading to treatment discontinuation or hesitation among patients and healthcare providers, thereby limiting overall therapy adoption.

Key Players In The Global Narcolepsy Market

Major companies operating in the narcolepsy market are Pfizer Inc., Merck & Co. Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries, Otsuka Pharmaceutical, Sumitomo Pharma Company Limited, Jazz Pharmaceuticals, Alkermes, Harmony Biosciences, Cerevel Therapeutics, Axsome Therapeutics Inc., Avadel Pharmaceuticals, NLS Pharmaceutics AG, KemPharm, Bioprojet Pharma, Centessa Pharmaceuticals, Hikma Pharmaceuticals, Theranexus SA, Eisai Co Ltd, Ligand Pharmaceuticals, Graymark Healthcare Inc, H Lundbeck A/S

Global Narcolepsy Market Trends and Insights

Major companies operating in the narcolepsy market are increasing their focus on developing novel medications, such as extended-release sodium oxybate, to address the growing demand for effective treatments. Extended-release sodium oxybate is a medication used in the treatment of narcolepsy. The extended-release formulation allows for controlled release of the medication over a longer period, providing sustained symptom relief throughout the night and improving sleep quality for individuals with narcolepsy. For instance, in June 2023, Avadel Pharmaceuticals plc, an Ireland-based pharmaceutical company, launched LUMRYZ in the United States. LUMRYZ is an extended-release formulation of sodium oxybate approved by the FDA for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. It is the first and only once-at-bedtime oxybate treatment for narcolepsy, offering a significant improvement over twice-nightly oxybate products by avoiding the need to wake up for a second dose at night.

What Are Latest Mergers And Acquisitions In The Narcolepsy Market?

In December 2023, NLS Pharmaceutics AG, a Switzerland-based pharmaceutical company, acquired a dual orexin receptor agonist platform from Aexon Labs Inc. for an undisclosed amount. The acquisition grants NLS Pharmaceutics the option to in-license all of Aexon Labs' assets for the treatment of narcolepsy and other neurodegenerative disorders, as well as global rights to multiple highly selective orexin-1/orexin-2 receptor agonists. Aexon Labs Inc. is a US-based company involved in the development of treatments for narcolepsy and neurodegenerative disease.

What Defines the Narcolepsy Market?

The narcolepsy market consists of revenues earned by entities by providing services such as cognitive behavioral therapy, telemedicine consultations, lifestyle management programs, and patient education programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The narcolepsy market also includes sales of dietary supplements, Pitolisant, Modafinil, and Armodafinil. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Narcolepsy Market Report 2026?

The narcolepsy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the narcolepsy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.